| Project/Area Number |
15K19692
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | メラノーマ / 熱ショック因子HSF1 / 熱ショック応答 / melanoma / HSF1 / triptolide / heat shock factor 1 / トリプトライド |
|---|
| Outline of Final Research Achievements |
Heat shock factor 1 (HSF1) is a major transactivator of the heat shock response. Recent studies have demonstrated that HSF1 is involved in tumor initiation, maintenance, and progression by regulating the expression of heat shock proteins (HSPs) and other molecular targets. Furthermore, HSF1 was identified as a potent proinvasion oncogene in human melanomas. Our previous studies demonstrated that silencing HSF1 suppressed proliferation, migration and invasiveness of human melanoma cells in vitro and HSF1 is required for melanoma invasion and metastasis, as well as tumorigenic potential in vivo. Triptolide is a pharmacologically active compound that has previously been shown to abrogate transactivation of HSF1. In this study, we found that triptolide suppressed tumorigenic potential of human melanoma via inhibiting transactivation of HSF1. These findings suggest that HSF1 could be a promising new therapeutic target for melanoma patient.
|
